Roche enters antibody collaboration with BD Biosciences

The companies hope that these antibodies will improve their understanding of the pathways that carry information inside of cells and why these pathways sometimes malfunction to cause disease. They also believe these insights could ultimately lead to the discovery of new drugs and biological markers for life-threatening and debilitating conditions.

BD Phosflow cell signaling antibodies-used in conjunction with BD's multi-parameter flow cytometry platforms, allow drug researchers to study specific subtypes of cells within a complex heterogeneous population and detect the activation state of multiple proteins at the single cell level.

“This is a potentially very powerful technology that will enable us to understand the molecular basis of complex heterogeneous disorders,” said Anthony Manning, vice president and global head of Inflammation, Autoimmunity and Transplantation Research at Roche.

“This knowledge will allow us to build on the joint efforts of Roche's pharmaceuticals and diagnostics divisions to create more effective and safer medicines by tailoring the drug to the right patient population.”